Monogram Technologies INC Form 4 insider transactions

Monogram Technologies Director Colleen Gray's stock options were cancelled and converted into cash and contingent value rights following the merger with Zimmer Biomet.

Monogram Technologies Inc. Director Colleen Gray acquired 5,000 stock options with an exercise price of $2.50, increasing her total beneficial ownership of derivative securities to 8,000, though the Form 4 was filed significantly late.

Richard Van Kirk's Monogram Technologies stock options were cancelled and converted into cash and CVRs following the merger with Zimmer Biomet.

Monogram Technologies Director Douglas Unis reported the disposition of common stock and stock options following the company's merger with Zimmer Biomet.

Monogram Technologies Chief Technology Officer Kamran Shamaei's shares and options were converted into cash and contingent value rights following the merger with Zimmer Biomet.

Monogram Technologies' CEO, Benjamin Sexson, reported the disposal of common stock and stock options following the company's merger with Zimmer Biomet Holdings, Inc.

Monogram Technologies director Paul Riss's stock options were cancelled and converted into cash and contingent value rights following the merger with Zimmer Biomet.

Monogram Technologies CFO Noel Knape disposed of all common stock and stock options following the company's merger with Zimmer Biomet's subsidiary.

Monogram Technologies Inc. Director Paul H. Riss acquired 10,000 stock options with an exercise price of $2.50, increasing his total beneficial ownership to 40,000 derivative securities.

Monogram Technologies Inc. Director Douglas Unis acquired 35,000 stock options with an exercise price of $2.50, effective January 8, 2025.

Monogram Technologies' Chief Technology Officer, Kamran Shamaei, acquired 250,000 stock options with an exercise price of $2.50, effective January 8, 2025.

Monogram Technologies Inc. CEO Benjamin Sexson acquired 160,000 stock options with an exercise price of $2.50, increasing his direct beneficial ownership to 1,560,000 derivative securities.

Monogram Technologies Inc.'s Chief Financial Officer, Noel Knape, acquired 40,000 stock options with an exercise price of $2.50, exercisable from January 8, 2032.

Monogram Technologies Inc. Director Richard Van Kirk Jr. acquired 5,000 stock options with an exercise price of $2.50, effective January 8, 2025.

Monogram Technologies and Zimmer Biomet voluntarily withdrew and resubmitted their HSR filing to allow the FTC more time for merger review, extending the waiting period until October 6, 2025.

Monogram Technologies' Chief Financial Officer, Noel Knape, acquired 288,461 shares of common stock at a price of $2.08 per share.

Noel Knape, CFO of Monogram Orthopaedics, reports the acquisition of 25,000 stock options on April 24, 2024.